NCT00742963 2025-05-13
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
ImmunoGenesis
Phase 1/2 Completed
ImmunoGenesis
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals
Threshold Pharmaceuticals